Cost-Effectiveness

Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis
abstract Background and Aims Medications for opioid use disorder (MOUD) are shown to reduce opioid use and the risk of overdose. People with opioid use disorder (OUD) who exit inpatient medically managed withdrawal programs (detox) without initiating MOUD and linking to outpatient care have high rates of overdose.
Alexandra Savinkina, Rajapaksha WMA Madushani, Golnaz Eftekhari Yazdi, Jianing Wang, Joshua A Barocas, Jake R Morgan, Sabrina A Assoumou, Alexander Y Walley, Benjamin P Linas, Sean M Murphy
Cite DOI Link
Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
abstract Aim To estimate the number of treatment initiations, averted fatal opioid overdoses and the cost-effectiveness associated with offering buprenorphine–naloxone (buprenorphine) treatment on-site within existing syringe service programs (SSPs) in Massachusetts, USA.
Joëlla W Adams, Alexandra Savinkina, Aaron Fox, Czarina N Behrends, Rajapaksha WMA Madushani, Jianing Wang, Avik Chatterjee, Alexander Y Walley, Joshua A Barocas, Benjamin P Linas
Cite DOI Link
Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study
abstract Background The opioid epidemic has been associated with an increase in hepatitis C virus (HCV) infections. Federally qualified health centers (FQHCs) have a high burden of hepatitis C disease and could serve as venues to enhance testing and treatment.
Sabrina A Assoumou, Shayla Nolen, Liesl Hagan, Jianing Wang, Golnaz Eftekhari Yazdi, William W Thompson, Kenneth H Mayer, Jon Puro, Lin Zhu, Joshua A Salomon, Benjamin P Linas
Cite Link
Cost-effectiveness and budgetary impact of hepatitis C virus testing, treatment, and linkage to care in US prisons
abstract Background Hepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release.
Sabrina A Assoumou, Abriana Tasillo, Claudia Vellozzi, Golnaz Eftekhari Yazdi, Jianing Wang, Shayla Nolen, Liesl Hagan, William Thompson, Liisa M Randall, Lara Strick, Joshua A Salomon, Benjamin P Linas
Cite DOI Link
Population-level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States
abstract Background The US Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born 1945–1965 and targeted testing for high-risk persons.
Joshua A Barocas, Abriana Tasillo, Golnaz Eftekhari Yazdi, Jianing Wang, Claudia Vellozzi, Susan Hariri, Cheryl Isenhour, Liisa Randall, John W Ward, Jonathan Mermin, Joshua A Salomon, enjamin P Linas
Cite DOI Link